Ovid Therapeutics Inc.2025财年第一财季实现净利润-10.24百万美元，同比增加12.40%

市场透视2025-05-19

5月19日，Ovid Therapeutics Inc.（OVID.US）公布财报，公告显示公司2025财年第一财季净利润为-10.24百万美元，同比增加12.40%；其中营业收入为130000.00美元，同比减少12.16%，每股基本收益为-0.14美元。从资产负债表来看，Ovid Therapeutics Inc.（OVID.US）总负债22.38百万美元，其中短期债务1.36百万美元，...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2536834594?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-05-19 00:01","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2536834594","market":"us","top_or_hot":-1,"title":"Ovid Therapeutics Inc.2025财年第一财季实现净利润-10.24百万美元，同比增加12.40%","media":"市场透视","content":"<div>\n<p>5月19日，Ovid Therapeutics Inc.（OVID.US）公布财报，公告显示公司2025财年第一财季净利润为-10.24百万美元，同比增加12.40%；其中营业收入为130000.00美元，同比减少12.16%，每股基本收益为-0.14美元。从资产负债表来看，Ovid Therapeutics Inc.（OVID.US）总负债22.38百万美元，其中短期债务1.36百万美元，...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250519000554a482f16e&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Ovid Therapeutics Inc.2025财年第一财季实现净利润-10.24百万美元，同比增加12.40%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nOvid Therapeutics Inc.2025财年第一财季实现净利润-10.24百万美元，同比增加12.40%\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-05-19 00:01 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250519000554a482f16e&s=b><strong>市场透视</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>5月19日，Ovid Therapeutics Inc.（OVID.US）公布财报，公告显示公司2025财年第一财季净利润为-10.24百万美元，同比增加12.40%；其中营业收入为130000.00美元，同比减少12.16%，每股基本收益为-0.14美元。从资产负债表来看，Ovid Therapeutics Inc.（OVID.US）总负债22.38百万美元，其中短期债务1.36百万美元，...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250519000554a482f16e&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LENZ","symbol_name":"Therapeutics","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250519000554a482f16e&s=b","article_id":"2536834594","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250519000554a482f16e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2536834594","pubTimestamp":1747584097,"columns":[],"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"5月19日，Ovid Therapeutics Inc.公布财报，公告显示公司2025财年第一财季净利润为-10.24百万美元，同比增加12.40%；其中营业收入为130000.00美元，同比减少12.16%，每股基本收益为-0.14美元。机构评级：截至2025年5月19日，当前有4家机构对Ovid Therapeutics Inc.目标价做出预测，其中目标均价为3.00美元，其中最低目标价为2.00美元，最高目标价为4.00美元。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":["earning"],"viewcount":null,"language":"zh","relate_stocks":{"LENZ":"Therapeutics","OVID":"Ovid Therapeutics Inc."},"translate_title":"Ovid Therapeutics Inc. achieved net profits of-US $10.24 million in the first fiscal quarter of fiscal year 2025, a year-on-year increase of 12.40%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LENZ":1,"OVID":1},"content_text":"5月19日，Ovid Therapeutics Inc.（OVID.US）公布财报，公告显示公司2025财年第一财季净利润为-10.24百万美元，同比增加12.40%；其中营业收入为130000.00美元，同比减少12.16%，每股基本收益为-0.14美元。从资产负债表来看，Ovid Therapeutics Inc.（OVID.US）总负债22.38百万美元，其中短期债务1.36百万美元，资产负债比为3.65，流动比率为4.94。机构评级：截至2025年5月19日，当前有4家机构对Ovid Therapeutics Inc.目标价做出预测，其中目标均价为3.00美元，其中最低目标价为2.00美元，最高目标价为4.00美元。公司简介：Ovid Therapeutics Inc是一家生物制药公司，致力于减少癫痫发作并切实改善被罕见癫痫和癫痫相关神经系统疾病影响的患者的生活。 该公司已经建立了差异化的药物管线，具有治疗癫痫发作的潜在一流药物作用机制。 该管线已经产生了两个具有潜在一流作用机制的癫痫项目，以及一个具有潜在一流作用机制的癫痫项目。（以上内容为腾讯自选股基于公开消息，由程序或算法智能生成，仅作为用户看盘参考，不作为投资建议或交易依据。股市有风险，请谨慎决策。）","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.13","shortVersion":"4.35.13","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2536834594","isCrawlerRequest":true}